A phase I randomized, double-blind, controlled trial of 2009 influenza A (H1N1) inactivated monovalent vaccines with different adjuvant systems

Vaccine

Volumn 29, Issue 48, 2011, Pages 8974-8981

  Precioso, Alexander R ^a,b   Miraglia, João L ^a   Campos, Lúcia Maria A ^b   Goulart, Alessandra C ^b   Timenetsky, Maria do Carmo S T ^c   Cardoso, Maria Regina A ^b   Luna, Expedito ^b   Mondini, Gabriella ^a   Guedes, José da S ^a   Raw, Isaias ^a  

^a INSTITUTO BUTANTAN   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c INSTITUTO ADOLFO LUTZ   (Brazil)

Author keywords

2009 Influenza A (H1N1) vaccine; Adjuvants; Clinical trial; Phase I

Indexed keywords

ALUMINUM HYDROXIDE; HEMAGGLUTININ; HEMAGGLUTININ ANTIGEN; IMMUNOLOGICAL ADJUVANT; INACTIVATED MONOVALENT VACCINE; INFLUENZA VACCINE; PLACEBO; SQUALENE; UNCLASSIFIED DRUG;

2009 H1N1 INFLUENZA; ADULT; ADVERSE OUTCOME; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FEMALE; GEOMETRY; HEADACHE; HEMAGGLUTINATION INHIBITION TEST; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INJECTION SITE PAIN; MALE; MULTICENTER STUDY; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION;

ADJUVANTS, IMMUNOLOGIC; ADULT; ALUMINUM HYDROXIDE; ANTIBODIES, VIRAL; ANTIBODY FORMATION; DOUBLE-BLIND METHOD; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; INJECTIONS, INTRAMUSCULAR; LIPID A; MALE; SQUALENE; VACCINES, INACTIVATED; YOUNG ADULT;

EID: 82455198738     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.09.040     Document Type: Article

References (37)

1. Lee V.J., Lye D.C., Wilder-Smith A. Combination strategies for pandemic influenza response-a systematic review of mathematical modeling studies. BMC Med 2009, 7:76.
2. Ferguson N.M., Cummings D.A., Fraser C., Cajka J.C., Cooley P.C., Burke D.S. Strategies for mitigating an influenza pandemic. Nature 2006, 442(July (7101)):448-452.
3. Enserink M. Swine flu pandemic. Developing countries to get some H1N1 vaccine-but when?. Science 2009, 326(November (5954)):782.
4. Bickel M., von Hentig N., Wieters I., Khaykin P., Nisius G., Haberl A., et al. Immune response after two doses of the novel split virion, adjuvanted pandemic H1N1 influenza A vaccine in HIV-1-infected patients. Clin Infect Dis 2011, 52(January (1)):122-127.
5. Zhu F.C., Wang H., Fang H.H., Yang J.G., Lin X.J., Liang X.F., et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med 2009, 361(December (25)):2414-2423.
6. Brown L.E. The role of adjuvants in vaccines for seasonal and pandemic influenza. Vaccine 2010, 28(November (50)):8043-8045.
7. WHO. Global alert and response: WHO recommendations on pandemic (H1N1) 2009 vaccines. Geneva: World Health Organization; 2009. [accessed 15.02.11]. http://www.who.int/csr/disease/swineflu/notes/h1n1_vaccine_20090713/en/index.html.
8. Wack A., Baudner B.C., Hilbert A.K., Manini I., Nuti S., Tavarini S., et al. Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. Vaccine 2008, 26(January (4)):552-561.
9. Leroux-Roels G. Unmet needs in modern vaccinology: adjuvants to improve the immune response. Vaccine 2010, 28(August (Suppl. 3)):C25-C36.
10. Gupta R.K. Aluminum compounds as vaccine adjuvants. Adv Drug Deliv Rev 1998, 32(July (3)):155-172.
11. Esposito S., Pugni L., Daleno C., Ronchi A., Valzano A., Serra D., et al. Influenza A/H1N1 MF59-adjuvanted vaccine in preterm and term children aged 6 to 23 months. Pediatrics 2011, 127(May (5)):e1161-e1168.
12. Clark T.W., Pareek M., Hoschler K., Dillon H., Nicholson K.G., Groth N., et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009, 361(December (25)):2424-2435.
13. Manuel O., Pascual M., Hoschler K., Giulieri S., Alves D., Ellefsen K., et al. Humoral response to the influenza A H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients. Clin Infect Dis 2011, 52(January (2)):248-256.
14. Didierlaurent A.M., Morel S., Lockman L., Giannini S.L., Bisteau M., Carlsen H., et al. AS04, an aluminum salt-and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol 2009, 183(November (10)):6186-6197.
15. Giannini S.L., Hanon E., Moris P., Van Mechelen M., Morel S., Dessy F., et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 2006, 24(August (33-34)):5937-5949.
16. Leroux-Roels G. Unmet needs in modern vaccinology: adjuvants to improve the immune response. Vaccine; 2010 28(August(Suppl. 3)) C25-36.
17. Brunner R., Jensen-Jarolim E., Pali-Scholl I. The ABC of clinical and experimental adjuvants-a brief overview. Immunol Lett;128(January(1)): 2010, 128(January (1)):29-35.
18. Quintilio W., Kubrusly F.S., Iourtov D., Miyaki C., Sakauchi M.A., Lucio F., et al. Bordetella pertussis monophosphoryl lipid A as adjuvant for inactivated split virion influenza vaccine in mice. Vaccine 2009, 27(June (31)):4219-4224.
19. ICH. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Guideline for Good Clinical Practice E6(R1). Current Step 4 version; 1996. [accessed 15.02.11]. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6_R1/Step4/E6_R1__Guideline.pdf.
20. World Health Organization (WHO). Availability of a candidate reassortant vaccine virus for the novel influenza A (H1N1) vaccine development; 2009. [accessed 25.02.09]. http://www.who.int/csr/resources/publications/swineflu/ivr153_20090608_en.pdf.
21. EMA. Committee for Proprietary Medicinal Products. Note for Guidance on Harmonisation of Requirements for Influenza Vaccines. London: European Medicines Agency, Publication no. CPMP/BWP/214/96; 1996. [accessed 15.02.11]. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003945.pdf.
22. EMA. European Committee for Proprietary Medicinal Products. Guideline on dossier structure and content for pandemic Influenza vaccine marketing authorisation application, CPMP/VEG/4717/03. London: European Agency for the Evaluation of Medicinal Products; 2004. http://archives.who.int/prioritymeds/report/append/62EMEAguidelines.pdf.
23. Kendal A.P., Pereira M.S., Skehel J.J. Concepts and procedures for laboratory-based influenza surveillance 1982, Centers for Disease Control and Prevention and Pan American Health Organization, Atlanta, Georgia, United States, p. B17-B35.
24. MS. Balanço parcial da vacinação contra a gripe A (H1N1). Brasil: Ministério da Saúde; 2010. [accessed 15.02.11]. http://portal.saude.gov.br/portal/arquivos/pdf/gripe_180610.pdf.
25. MS/SVS/DVE/PNI. Estratégia Nacional de Vacinação Contra o Vírus Influenza Pandêmico (H1N1) 2009. Brasil: Ministério da Saúde, Secretaria de Vigilância em Saúde, Departamento de Vigilância Epidemiológica, Programa Nacional de Imunizações;. [accessed 15.02.11]. http://www.conass.org.br/arquivos/file/informetecnico_05_03.pdf.
26. Brewer J.M., Conacher M., Satoskar A., Bluethmann H., Alexander J. In interleukin-4-deficient mice, alum not only generates T helper 1 responses equivalent to freund's complete adjuvant, but continues to induce T helper 2 cytokine production. Eur J Immunol 1996, 26(September (9)):2062-2066.
27. Coffman R.L., Sher A., Seder R.A. Vaccine adjuvants: putting innate immunity to work. Immunity 2010, 33(October (4)):492-503.
28. HogenEsch H. Mechanisms of stimulation of the immune response by aluminum adjuvants. Vaccine 2002, 20(May (Suppl. 3)):S34-S39.
29. Kool M., Petrilli V., De Smedt T., Rolaz A., Hammad H., van Nimwegen M., et al. Cutting edge: alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome. J Immunol 2008, 181(September (6)):3755-3759.
30. Eisenbarth S.C., Colegio O.R., O'Connor W., Sutterwala F.S., Flavell R.A. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 2008, 453(June (7198)):1122-1126.
31. Seubert A., Monaci E., Pizza M., O'Hagan D.T., Wack A. The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. J Immunol 2008, 180(April (8)):5402-5412.
32. Dupuis M., Murphy T.J., Higgins D., Ugozzoli M., van Nest G., Ott G., et al. Dendritic cells internalize vaccine adjuvant after intramuscular injection. Cell Immunol 1998, 186(May (1)):18-27.
33. Casella C.R., Mitchell T.C. Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell Mol Life Sci 2008, 65(October (20)):3231-3240.
34. Mata-Haro V., Cekic C., Martin M., Chilton P.M., Casella C.R., Mitchell T.C. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 2007, 316(June (5831)):1628-1632.
35. USFDA. Guidance for industry: clinical data needed to support the licensure of pandemic influenza vaccines. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; 2007. [accessed 20.02.11]. http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm091985.pdf.
36. Bresson J.L., Perronne C., Launay O., Gerdil C., Saville M., Wood J., et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 2006, 367(May (9523)):1657-1664.
37. Greenberg M.E., Lai M.H., Hartel G.F., Wichems C.H., Gittleson C., Bennet J., et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 2009, 361(December (25)):2405-2413.